Anavex Life Sciences Corp. (AVXL) vs. Its Competitors Head-To-Head Analysis
Anavex Life Sciences Corp. (NASDAQ: AVXL) is one of 93 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Anavex Life Sciences Corp. to related companies based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Volatility and Risk
Anavex Life Sciences Corp. has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp.’s competitors have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
This table compares Anavex Life Sciences Corp. and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences Corp.||N/A||-95.68%||-84.88%|
|Anavex Life Sciences Corp. Competitors||-919.42%||-189.81%||-26.55%|
Earnings & Valuation
This table compares Anavex Life Sciences Corp. and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Anavex Life Sciences Corp.||N/A||-$15.61 million||-11.23|
|Anavex Life Sciences Corp. Competitors||$223.74 million||$57.84 million||-0.71|
Anavex Life Sciences Corp.’s competitors have higher revenue and earnings than Anavex Life Sciences Corp.. Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
24.4% of Anavex Life Sciences Corp. shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 11.6% of Anavex Life Sciences Corp. shares are held by company insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings for Anavex Life Sciences Corp. and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences Corp.||0||0||3||0||3.00|
|Anavex Life Sciences Corp. Competitors||164||547||1204||16||2.56|
Anavex Life Sciences Corp. currently has a consensus target price of $13.67, suggesting a potential upside of 212.02%. As a group, “Biotechnology” companies have a potential upside of 50.94%. Given Anavex Life Sciences Corp.’s stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences Corp. is more favorable than its competitors.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.